Literature DB >> 16868033

Variability of CYP2J2 expression in human fetal tissues.

Andrea Gaedigk1, Darren W Baker, Rheem A Totah, Roger Gaedigk, Robin E Pearce, Carrie A Vyhlidal, Darryl C Zeldin, J Steven Leeder.   

Abstract

CYP2J2 metabolizes arachidonic acid to 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids (EETs), which play a critical role in the regulation of renal, pulmonary, cardiac, and vascular function. However, the contribution of CYP2J2 to EET formation in the liver remains poorly characterized. Likewise, information is sparse regarding the extent and variability of CYP2J2 expression during human development. This investigation was undertaken to characterize the variability of CYP2J2 expression in fetal liver, heart, kidney, lung, intestine, and brain and in postnatal liver samples. CYP2J2 mRNA expression was measured using quantitative polymerase chain reaction, and immunoreactive CYP2J2 was examined using two anti-CYP2J2 antibodies. CYP2J2 mRNA was ubiquitously expressed in pre- and postnatal samples. Fetal hepatic mRNA expression varied 127-fold (1351 +/- 717 transcripts/ng total RNA), but this variation was reduced to 8-fold after exclusion of four samples with extremely low levels of mRNA. Amounts of immunoreactive protein also varied substantially among samples without an apparent relationship with transcript number or genotype. Western blot analysis revealed a different protein pattern between prenatal and postnatal liver samples. DNA resequencing of selected subjects identified a single novel single-nucleotide polymorphism (CYP2J2*10), which was found in only one subject and therefore did not explain the large variability in CYP2J2 protein content. In vitro expression suggests that the protein product of CYP2J2*10 confers reduced enzymatic activity. Aberrant splicing produces three minor transcripts, which were present in all samples tested. Due to premature termination codons, none encodes functional protein. The mechanisms leading to variable amounts of immunoreactive protein and distinct pre- and postnatal CYP2J2 protein patterns warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16868033      PMCID: PMC1876721          DOI: 10.1124/jpet.106.109215

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

1.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

Authors:  P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

2.  Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes.

Authors:  Takanori Hashizume; Susumu Imaoka; Masashi Mise; Yoshiaki Terauchi; Toshihiko Fujii; Hisashi Miyazaki; Tetsuya Kamataki; Yoshihiko Funae
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

3.  Expression of biotransformation enzymes in human fetal olfactory mucosa: potential roles in developmental toxicity.

Authors:  J Gu; T Su; Y Chen; Q Y Zhang; X Ding
Journal:  Toxicol Appl Pharmacol       Date:  2000-06-01       Impact factor: 4.219

4.  Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney.

Authors:  Z Yu; L M Huse; P Adler; L Graham; J Ma; D C Zeldin; D L Kroetz
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

5.  Interaction of apo-cytochrome b5 with cytochromes P4503A4 and P45017A: relevance of heme transfer reactions.

Authors:  O L Guryev; A A Gilep; S A Usanov; R W Estabrook
Journal:  Biochemistry       Date:  2001-04-24       Impact factor: 3.162

6.  Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole.

Authors:  Shigeki Matsumoto; Tomoe Hirama; Tsutomu Matsubara; Kiyoshi Nagata; Yasushi Yamazoe
Journal:  Drug Metab Dispos       Date:  2002-11       Impact factor: 3.922

7.  Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations.

Authors:  Peter K Rogan; Stan Svojanovsky; J Steven Leeder
Journal:  Pharmacogenetics       Date:  2003-04

8.  Cloning of CYP2J2 gene and identification of functional polymorphisms.

Authors:  Lorraine M King; Jixiang Ma; Supawon Srettabunjong; Joan Graves; J Alyce Bradbury; Leping Li; Martin Spiecker; James K Liao; Harvey Mohrenweiser; Darryl C Zeldin
Journal:  Mol Pharmacol       Date:  2002-04       Impact factor: 4.436

Review 9.  P-450 metabolites of arachidonic acid in the control of cardiovascular function.

Authors:  Richard J Roman
Journal:  Physiol Rev       Date:  2002-01       Impact factor: 37.312

10.  Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.

Authors:  Ina Koch; Regina Weil; Renzo Wolbold; Jürgen Brockmöller; Elisabeth Hustert; Oliver Burk; Andreas Nuessler; Peter Neuhaus; Michel Eichelbaum; Ulrich Zanger; Leszek Wojnowski
Journal:  Drug Metab Dispos       Date:  2002-10       Impact factor: 3.922

View more
  19 in total

1.  Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues.

Authors:  Tracy C Delozier; Grace E Kissling; Sherry J Coulter; Diana Dai; Julie F Foley; J Alyce Bradbury; Elizabeth Murphy; Charles Steenbergen; Darryl C Zeldin; Joyce A Goldstein
Journal:  Drug Metab Dispos       Date:  2007-01-12       Impact factor: 3.922

2.  Ontogeny of novel cytochrome P450 gene isoforms during postnatal liver maturation in mice.

Authors:  Julia Yue Cui; Helen J Renaud; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2012-03-23       Impact factor: 3.922

3.  Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.

Authors:  Goutam Chowdhury; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-12-24       Impact factor: 3.739

4.  PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2.

Authors:  Dorit S Berlin; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-05       Impact factor: 2.089

5.  Impaired transactivation of the human CYP2J2 arachidonic acid epoxygenase gene in HepG2 cells subjected to nitrative stress.

Authors:  Pei H Cui; Andy C Lee; Fanfan Zhou; Michael Murray
Journal:  Br J Pharmacol       Date:  2010-02-24       Impact factor: 8.739

6.  CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPARγ.

Authors:  Rui Li; Xizhen Xu; Chen Chen; Yan Wang; Artiom Gruzdev; Darryl C Zeldin; Dao Wen Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-11-11       Impact factor: 4.310

Review 7.  Roles of the epoxygenase CYP2J2 in the endothelium.

Authors:  Ara Askari; Scott J Thomson; Matthew L Edin; Darryl C Zeldin; David Bishop-Bailey
Journal:  Prostaglandins Other Lipid Mediat       Date:  2013-03-06       Impact factor: 3.072

Review 8.  Maternal-fetal and neonatal pharmacogenomics: a review of current literature.

Authors:  Y J Blumenfeld; M F Reynolds-May; R B Altman; Y Y El-Sayed
Journal:  J Perinatol       Date:  2009-11-19       Impact factor: 2.521

9.  Eicosanomic profiling reveals dominance of the epoxygenase pathway in human amniotic fluid at term in spontaneous labor.

Authors:  Krishna Rao Maddipati; Roberto Romero; Tinnakorn Chaiworapongsa; Sen-Lin Zhou; Zhonghui Xu; Adi L Tarca; Juan Pedro Kusanovic; Hernan Munoz; Kenneth V Honn
Journal:  FASEB J       Date:  2014-07-24       Impact factor: 5.191

10.  Three patterns of cytochrome P450 gene expression during liver maturation in mice.

Authors:  Steven N Hart; Yue Cui; Curtis D Klaassen; Xiao-bo Zhong
Journal:  Drug Metab Dispos       Date:  2008-10-09       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.